Stacy R. Nerenstone, M.D., Medical Oncologist
Undergraduate: Brown University - 1977 BA
Medical School: Columbia University School of Medicine -1981 MD
Residency: Beth Israel Hospital 1981-1984 Internal Medicine
Fellowship: National Cancer Institute (NYC) 1984-1989 Medical Oncology, Clinical Trials Research
President of the Hartford Hospital Medical Staff
President of the Hartford Hospital Physicians' Association
President of Oncology Associates
Board member of Hartford Hospital and Integrated Care Partners
Board member of the Executive Committee of the Cancer Institute of Hartford Healthcare
Member of Disease Management Teams for Breast Cancer and Gynecologic Cancers
Member of the NRG Oncology Safety Review Committee
Assistant Clinical Professor at the University of Connecticut School of Medicine
Member of the American Society of Clinical Oncology (ASCO)
Previous member of the Oncology Drug Advisory Committee to the FDA
Previous Oncology Drug Advisory Committee Chairman
Harvard University Instructor in Medicine, 1981-1984
- Moore, T., Phillips, P., Nerenstone, S., & Cheson, B. (1991). Systemic treatment of advanced and recurrent endometrial carcinoma: Current status and future directions. Journal of Clinical Oncology, 9(6), 1071-1088.
- Agraharkat, M., Nerenstone, S., Palmmisano, J., & Kaplan, A. (1998). Carboplatin-related hematuria and acute renal failure. American Journal of Kidney Diseases, 32, 1-5.
- Rose, P., Nerenstone, S., Brady, M., et al. Secondary surgical Cytoreduction for advanced ovarian carcinoma. New England Journal of Medicine, 351, 2489-97.
- Rose, P.G., Nerenstone, S., Brady, M., et al. A Phase III randomized study of interval secondary Cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: A gynecologic oncology group study. Procaso, 21, 802.
AREAS OF INTEREST